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Abstract The cell adhesion molecule CD2 facilitates antigen-independent T-cell activation
and CD2 deficiency or blockade reduces intestinal inflammation in murine models. We here
aimed to evaluate the therapeutic potential of monoclonal antibodies (mAb) specific for human
CD2 in colitis treatment. Transfer colitis induced by naïve CD4+ T cells expressing human CD2
was treated with anti-human CD2 mAb. The mAb CB.219 protected from severe colitis in a
preventive treatment regimen, while therapeutic treatment ameliorated intestinal inflamma-
tion. Diminished intestinal tissue damage was paralleled by a profound suppression of lamina
propria lymphocytes to produce pro-inflammatory cytokines and tumor necrosis factor α as well
as the neutrophil chemoattractant CXC motif ligand 1 and the CC chemokine ligand 3.
Furthermore, infiltration with macrophages and T cells was low. Thus, reduced intestinalligand; CXCL, CXC-motif ligand; FoxP3, forkhead box protein 3; hpf, high power field; huCD2tg, mice
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17CB.219 therapy reduces humanized transfer colitisinflammation in our humanized colitis model by targeting CD2 on T cells with the mAb CB.219
suggests a novel approach for colitis treatment.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dysregulated mucosal immune responses in inflammatory
bowel diseases (IBD) are thought to result from the loss of
tolerance to the autologous gut microbiota or to food
antigens [1,2]. Initiated by the innate immune system,
inflammatory processes in chronic disease are maintained by
adaptive immune responses [3,4]. Here, activated T cells
modulated by the local cytokine milieu in the presence of
antigen-presenting cells assist the recruitment of additional
immune cells into the local environment. Breaking this
vicious circle and re-establishing a regulated immune
balance provides the main therapeutic aim in IBD [5,6].
Virtually all T and natural killer cells, main populations at the
interface of innate and adapted immune responses involved in
the initiation and perpetuation of IBD, express the glycoprotein
CD2 [7,8]. In terms of an adhesion molecule, this member of the
immunoglobulin (Ig) superfamily is part of the immunological
synapse and interacts in humans with the ubiquitously expressed
lymphocyte function-associated antigen-3 (CD58) [9,10]. CD48,
the ligand for CD2-dependent T-cell activation in rodents has
only a low affinity to human CD2 [11–13]. As an accessory
molecule CD2 lowers the threshold of antigen-specific T-cell
responses [14]. CD2 expression closely relates to important
differences between local mucosal and systemic immune
responses: Stimulation of lamina propria lymphocytes (LPL) via
CD2 results in proliferation and apoptosis, while peripheral T
cells rather respond to CD3/T-cell receptor-mediated stimula-
tion [15,16]. Targeting humanCD2 by specific antibodies induces
hypo-responsiveness and apoptosis in human T cells in vitro
[17–19]—mechanisms that translate to the break of T cell-driven
steroid-refractory acute graft-versus-host disease in adults
[20–24]. Alefacept, a completely humanized fusion protein of
a CD2 binding domain of CD58 with IgG1, effectively eliminates
effector/memory T cells and inhibits T-cell co-stimulation
[25,26]. It has been approved for the treatment of psoriasis, a
chronic inflammatory disease that mainly affects skin and joints
[27]. In a transfer colitis model with murine naïve T cells,
targeting CD2 specifically reduced intestinal inflammation [28].
Against this background, targeting CD2 could also serve to
therapeutically address the dysbalanced mucosal T-cell re-
sponse in human IBD. Focusing on T cells, we asked in a
humanized model of T-cell-mediated colitis using naïve CD4+ T
cells isolated from mice expressing human CD2 (huCD2tg)
whether monoclonal antibodies specific for human CD2 can
abrogate mucosal inflammation.
2. Materials and methods
2.1. Animals
HuCD2tg mice [29] obtained from D. Kioussis (London, UK)
were bred under specific pathogen-free conditions at theForschungseinrichtungen für Experimentelle Medizin (Berlin).
Wild-type C57BL/6 and recombination activating gene
1-deficient C57BL/6 J-Ragtm1Mom (Rag1-ko) mice were pur-
chased from the Jackson Laboratory (Bar Harbor). All exper-
iments were performed in accordance with the German
legislation on the protection of animals (Tierschutzgesetz;
permit G0207/05).
2.2. Antibodies used in vivo
Anti-human CD2 monoclonal antibodies were purified by
Protein A Sepharose-affinity chromatography (GE Healthcare,
Freiburg) from culture supernatants of the hybridoma lines
CB.219 [30] (mouse IgG2b; kindly provided by B. Fleischer,
Hamburg), ICRFCD2.1.1a/8E5 [31] (8E5; mouse IgG2a; kindly
provided by B. Schraven, Heidelberg) or 35.1 [32] (mouse
IgG2a; ATCC/LCG Standards, Wesel). Purified antibodies
were lyophilized and reconstituted at 1 mg/mL in sterile
phosphate-buffered saline (PBS; PAA Laboratories, Cölbe).
Aliquots of 200 μL were snap frozen in liquid nitrogen and
stored at −80 °C. For anti-human CD2 treatment, 200 μg
purified anti-human CD2 of the clones 35.1, 8E5 or CB.219 was
injected intraperitoneally. Control mice received 200 μg
polyclonal mouse IgG (Dianova, Hamburg) in comparable
treatment regimens.
2.3. Induction of transfer colitis
CD4+CD45RBhi T cells were isolated from spleen cells of huCD2tg
mice by positive magnetic cell separation according to the
manufacturer's instructions (Miltenyi Biotech, Bergisch-
Gladbach) using anti-mouse CD4 monoclonal antibody (RM4-5)
and anti-mouse CD45RBmonoclonal antibody (16A; both fromBD
Biosciences, Heidelberg). Sorted CD4+CD45RBhi T cells were
subsequently washed and re-suspended at 4 × 105 cells/200 μL
in sterile PBS. Transfer colitis was induced in Rag1-ko mice as
described elsewhere [33]. The clinical course of colitis was
assessed by body weight, general behaviour and coat appear-
ance every third day after T-cell transfer. Stool samples were
examined for consistency and occult blood (Haemoccult;
Beckmann Coulter, Krefeld). Stool consistency was scored as
follows: 0, well-formed pellets; 1, pasty and semi-formed stool;
2, liquid stool; 3, liquid and bloody stool. Occult blood added
another point to the overall stool score. Animals were killed at
the end of the experiments or upon signs of severe colitis as
defined by N20% weight loss compared to the initial body
weight, lethargy, shagginess and positive Haemoccult test.
2.4. Histopathology
Samples of sigmoid colon and terminal ileum were fixed in
4% formaldehyde and embedded in paraffin (Sigma-Aldrich,
Taufkirchen). Thin sections (1–2 μm) were de-paraffinized,
18 CB.219 therapy reduces humanized transfer colitisstained with hematoxylin/eosin (Merck, Darmstadt) and
evaluated in a blinded manner. Transfer colitis was scored
as described elsewhere [34].
2.5. Immunohistochemistry
Thin sections of colon tissue were de-paraffinized and
subjected to heat-induced or protease-induced epitope re-
trieval. After blocking endogenous peroxidase, sections were
incubated with the following primary antibodies for 30 min at
room temperature: rat anti-mouse forkhead box protein 3
(Foxp3; clone FJK-16 s), rat anti-mouse F4/80 (clone BM8, both
from eBioscience, Frankfurt), rat anti-mouse Ki67 (clone TEC3;
Dako, Hamburg), polyclonal rabbit anti-mouse CD95 (X-20;
Santa Cruz, Heidelberg), polyclonal rabbit anti-mouse cleaved
caspase-3 (Asp175, 9661; Cell Signalling, Danvers) or polyclonal
rabbit anti-human CD3 cross-reacting with mouse CD3 (N1580;
Dako). After rinsing, the sections were incubated for 30 min at
room temperature with the following secondary antibodies:
rabbit anti-rat, biotinylated donkey anti- rat or biotinylated
donkey anti-rabbit (Dianova). The EnVision+ System with a
horseradish peroxidase-labeled polymeric anti-rabbit (Dako) in
combination with 3,3′-diaminobenzidine was used for detec-
tion. Alternatively biotinylated secondary antibodies were
followed by the streptavidin-alkaline phosphatase (Dako).
Alkaline phosphatase was revealed with Chromogen Red
(Dako). Primary antibodies were omitted in negative controls.
Sections were examined by light microscopy using an
AxioImager Z1 microscope and the AxioVision software (Carl
Zeiss MicroImaging, Oberkochen). For quantification, positively
stained cells in 10 hpf were counted.
2.6. Ex vivo organ culture
Segments (1 cm length) of sigmoid colon or terminal ileum
were opened longitudinally, rinsed in sterile PBS and placed in
48-well tissue-culture plates containing 500 μL basal medium
consisting of RPMI1640 supplemented with 100 U/mL penicil-
lin, 100 μg/mL streptomycin, 4 mmol/L L-glutamine (all from
PAA Laboratories) and 50 μmol/L β-mercaptoethanol
(Sigma-Aldrich). After 24 h, collected culture supernatants
were snap frozen over liquid nitrogen and stored at −80 °C.
2.7. Preparation of lamina propria lymphocytes (LPL)
A colon segment (2–4 cm length) was opened longitudinally
and cut into fragments of 0.5 cm2 that were rinsed in
sterile PBS and shaken in Hank's balanced salt solution
(PAA Laboratories) containing 1 mmol/L dithiothreitol and
2.5 μmol/L ethylenediaminetetraacetic acid for 45 min. Medi-
um was changed twice before the fragments were incubated in
complete medium that consisted of basal medium supple-
mented with 10% fetal bovine serum (Linaris, Bettingen),
1.792 U/mL collagenase II and 2.4 × 104 U/mL deoxyribonucle-
ase I (Calbiochem) for 90 min at 37 °C. Subsequently, the tissue
was passed through a 70 μm mesh cell strainer (BD Bioscience)
followed by density gradient centrifugation (100%:40% Percoll;
GE Healthcare). The LPL from the interphase were washed and
re-suspended in complete medium at 106/mL. Only LPL
preparations with viabilities N90% as determined by trypan
blue exclusion (Biochrom, Berlin) were used in experiments.2.8. LPL culture
Culture plates (24-well) were coated with 10 μg/mL
anti-mouse CD3ε purified from supernatants of hybridoma
culture (clone 145-2C11; LCG Standards) by Protein G-Sepha-
rose affinity chromatography (GE Healthcare). LPL (106/well)
were seeded to the plate and incubated for 48 h in the
presence of 1 μg/mL anti-mouse CD28 (clone 37.51; BD
Biosciences). Collected cell culture supernatants were snap
frozen over liquid nitrogen and stored at −80 °C.
2.9. Secreted cytokine and chemokine detection
Thawed culture supernatants were examined for secreted interferon
(IFN)γ, interleukin (IL)-2, IL-10 (all BD Biosciences) and transforming
growth factor (TGF)β (Promega, Mannheim) by sandwich
enzyme-linked immunosorbent assay according to themanufacturer's
instructions. Alternatively, these cytokines and in addition, IL-4, IL-6,
IL-12, IL-17A and tumor necrosis factor (TNF)α as well as the
chemokines CC chemokine ligand (CCL)2, CCL3 and CXC-motif ligand
(CXCL)1 were assessed by cytometric bead array using Flex sets
following themanufacturer's instructions (BD Biosciences). If applica-
ble, totalproteincontent in serum-free supernatantswasdetermined
bytheBio-Radproteinassay (Bio-Rad,Munich)andsecretedcytokines
were normalized to the protein amount (ng/mg protein).
2.10. Proliferation assay
LPL (5 × 104/well) were seeded to 96-well flat-bottom culture
plates coated with 10 μg/mL anti-mouse CD3ε (clone
145-2C11) and incubated for 96 h in the presence of 1 μg/mL
anti-CD28 (clone 37.51). Wells without anti-mouse CD3ε served
as negative controls. Each well received 0.5 μCi [6-3H]-thymi-
dine (GE Healthcare) during the last 18 h of the culture.
Incorporated [6-3H]-thymidine was harvested onto a glass fiber
membrane and radioactive decay was detected by liquid
scintillation counting (LKB Wallac, Turku). The proliferation
index was calculated as the ratio from related cultures with
and without stimulation via CD3/CD28.
2.11. Statistical analysis
Statistical analysis was carried out using SPSS (SPSS, Chicago)
forWindows (Microsoft, Redmond). Survival was analyzed using
Kaplan–Meier analysis. Box and whisker plots show lower and
upper quartiles, median as well as minimum and maximum
data. Circles indicate outliers. Differences were considered
significant for p b 0.05 as determined by Mann–Whitney
U test.
3. Results
3.1. Concurrent treatment with the anti-human
CD2 monoclonal antibody CB.219 protects from
development of colitis induced by naïve huCD2tg
CD4+ T cells.
In a preventive setting, monoclonal antibody treatment
started simultaneously with the transfer of CD4+CD45RBhi T
cells derived from huCD2tg mice into Rag1-ko mice. The
Figure 1 Course of transfer colitis in mice concurrently treated with anti-human CD2. (A) Schematic protocol for induction of
colitis by transfer of CD4+ CD45RBhigh T cells from huCD2tg mice into Rag1-ko mice and simultaneous start of treatment with
anti-human CD2 for 87 days. (B) Kaplan–Meier plot of the survival of mice that received anti-human CD2 of the clones CB.219 (n = 8),
35.1 (n = 8) or 8E5 (n = 8) or that were treated with control IgG (ctrl) (n = 9). (C) Weight change of individual mice at the end of the
experiment was determined in relation to the initial body weight at day 0. Mean and SEM of n = 8–9.
19CB.219 therapy reduces humanized transfer colitisantibodies of the clones CB.219 [30] and 8E5 [31] interact with
the N-terminal CD58-binding region of CD2, while the clone
35.1 is described to not to interfere with CD58-mediated
effects [32]. These CD2-specific antibodies as well as a control
IgG were given repeatedly every 3 days for up to 84 daysFigure 2 Histologic assessment of colitis following preventive treatme
the presence of anti-human CD2 of the clones CB.219, 35.1, 8E5 or w
eosin-stained colon sections. Original magnification ×100; scale bar: 10
sections. Median and range of n = 6–8. (C) Supernatants from organ cul(Fig. 1A). Due to severe colitis half of the mice in the
IgG-treated control group died until day 40 (Fig. 1B). Targeting
human CD2 by 8E5 and 35.1 prolonged the survival up to 60 or
80 days. All mice treatedwith the anti-humanCD2monoclonal
antibody CB.219 survived until the end of the experiment atntwith anti-human CD2mAb. Colitis in Rag1-komicewas induced in
ith control IgG (ctrl). (A) Representative images of hematoxylin/
0 μm. (B) Histologic scores from hematoxylin/eosin-stained colon
ture over 24 h were tested for TGFβ. Median and range of n = 7–8.
Table 1 Cytokine and chemokine production in the colon from mice treated with anti-human CD2 during induction of colitis.
Colon tissue from colitic mice treated with
Ctrl 35.1 8E5 CB.219
IFNγ ⁎ 525.7 ± 245.6 478.9 ± 121.0 935.3 ± 193.6 226.9 ± 55.2
IL-2 1.3 ± 0.4 1.4 ± 0.2 2.6 ± 0.9 17.0 ± 11.4
TNFα 19.0 ± 14.0 4.1 ± 0.7 28.9 ± 24.9 6.0 ± 0.3
IL-6 650.1 ± 209.0 577.9 ± 314.7 870.4 ± 183.5 896.9 ± 255.6
IL-4 3.3 ± 0.9 1.7 ± 0.3 1.6 ± 0.2 2.0 ± 0.0
IL-10 108.0 ± 66.1 27.9 ± 18.7 133.4 ± 107.2 187.0 ± 175.7
CXCL1 1,914.0 ± 519.9 1,126.0 ± 413.0 2,008.0 ± 626.6 3,059.0 ± 895.6
⁎ Colon samples from colitis following preventive treatment with anti-human CD2 (35.1: n = 7, 8E5: n = 7; CB.219: n = 8) or control IgG
(ctrl): n = 7) were subjected to in vitro culture for 24 h. Cytokines and chemokines as assessed from the culture supernatants were
normalized to its total protein content. Mean values given in ng/mg protein and SEM.
20 CB.219 therapy reduces humanized transfer colitisday 87. Complementing the survival benefit, CB.219-treated
mice continuously gained weight. At day 87, it was signifi-
cantly higher compared to all surviving mice of the other
groups (Fig. 1C).
At the end of the experiment, only histology of colon
tissue from CB.219-treated mice showed almost normal
appearance with minor leukocyte infiltrations (Fig. 2A).
Tissue morphology in animals treated with 8E5 or 35.1
targeting human CD2 or with the control IgG was comparablyFigure 3 Leukocyte infiltration into the colon tissue and state of the
sections of colon tissues of mice treated with anti-human CD2 or contr
cleaved caspase-3 and (B) for CD3 or Foxp3. Positive cells were counted i
colon tissues stained for cleaved caspase-3. Original magnification ×10
epithelium. (E) Total number of epithelial cells per crypt assessed in hem
from 10 crypts per section.altered. The colon sections of control animals indicated
leukocyte infiltration into mucosa and submucosa as well as
crypt epithelial cell hyperplasia. Treatment with 8E5 or 35.1
did not prevent additional loss of goblet cells. These
observations translated into significantly reduced histologic
scores in CB.219-treated mice compared to all other
treatment groups (Fig. 2B). As for the spontaneous cytokine
secretion, colon tissues showed no differences for IFNγ, IL-2,
IL-6, IL-4, IL-10 and TNFα as well as of the chemokine CXCL1epithelium after preventive treatment with anti-human CD2. Thin
ol IgG (ctrl) were stained by immunohistochemistry (A) for Ki67 or
n 10 hpf. Median and range of n = 7–8. (C) Representative images of
0. (D) Percentages of cleaved caspase-3+ epithelial cells in colonic
atoxylin/eosin-stained colon sections (also see Fig. 2A). Mean ± SEM
Figure 4 Effect of therapeutic CB.219 treatment of established transfer colitis. (A) Schematic protocol for induction of colitis by transfer
of CD4+ CD45RBhigh T cells from huCD2tg mice into Rag1-ko mice and subsequent repeated treatment of established colitis with CB.219 or
with control IgG (ctrl) for 37 days. (B) Establishment of colitis was confirmed from hematoxylin/eosin-stained colon sections at day 21 after
transfer of huCD2tg T cells before onset of antibody treatment. Arrowheads in the representative image point to mucosal and submucosal
leukocyte infiltration with occasional crypt abscesses; the dotted line indicates hyperplasia. Original magnification ×200; scale bar:
500 μm. (C) Kaplan–Meier plot of the survival of mice receiving CB.219 (n = 10) or control IgG (ctrl) (n = 9). The course of colitis after start
of antibody treatment was assessed (D) from stool consistency and occult blood as well as (E) from body weights in relation to individual
weights at day 0 before T-cell transfer over time and (F) at the end of the study. Mean and SEM of n = 9–10. (G) Hematoxylin/eosin-stained
sections of colon or terminal ileum tissue were scored histologically at the end of the experiment. Median and range of n = 9–10.
21CB.219 therapy reduces humanized transfer colitisin all groups (Table 1). Treatment with CB.219 significantly
increased intestinal TGFβ production compared to colon
tissue of mice treated with 8E5 or with control IgG (Fig. 2C).
Addressing the question of the fate of the transferred T cells
within the intestinal mucosa, apoptosis and proliferation were
studied by immunohistochemistry. Numbers of proliferating
Ki67+ and apoptotic cleaved caspase-3+ cells were significantly
lower in the colon mucosa of CB.219-treated mice than within
the other anti-human CD2-treated or in the control groups
(Fig. 3A). Reduced numbers of CD3+ T cells after treatmentwith
CB.219 included equally reduced counts of Foxp3+ regulatory T
cells (Treg) (Fig. 3B). The colonic epithelium of CB.219-treated
mice showed reduced signs of inflammation-related alterations
compared to all other groups tested. Epithelial cells were
significantly less prone to apoptosis (Fig. 3C, D) and to epithelial
cell proliferation as determined from the numbers of epithelial
cells per crypt that define the crypt length (Fig. 3E).Table 2 Cytokine production in colon or terminal ileum from co
Colon
Ctrl CB.219
IFNγ* 262.1 ± 103.1 172.4 ± 49.6
IL-2 b1.0 b1.0
IL-10 70.7 ± 29.5 8.1 ± 1.8
TGFβ 100.8 ± 60.8 2,663.0 ± 1,31
*Samples from colon and terminal ileum from transfer colitis following
day 22 were subjected to in vitro culture. IFNγ, IL-2, IL-10 and TGFβ sec
normalized to its total protein content. Mean values and SEM of 7–10 aTargeting human CD2 by the monoclonal antibody CB.219,
but not by 8E5 or 35.1, effectively counteracted severe colitis
development upon transfer of naïve CD4+ T cells from huCD2tg
into Rag1-ko mice as shown by unremarkable clinical signs,
low inflammatory cell infiltration in the colon tissue and
increased mucosal production of the anti-inflammatory
mediator TGFβ. They directly relate to a protection of the
intestinal epithelium.3.2. Targeting human CD2 by CB.219 ameliorates
inflammation in established huCD2tg CD4+ T-cell-
mediated transfer colitis.
As preventive treatment with CB.219 protected from devel-
opment of severe transfer colitis, we asked for the therapeutic
potential of this monoclonal antibody. To this end, inductionlitic mice treated with CB.219.
Terminal ileum
Ctrl CB.219
96.8 ± 49.7 14.7 ± 3.1
b1.0 b1.0
20.2 ± 0 b1.0
8.0 921.0 ± 695.4 66.6 ± 31.2*
therapeutic treatment with CB.219 or control IgG (ctrl) starting at
reted within 24 h were assessed from the culture supernatants and
nimals given in ng/mg protein. *p = 0.019 compared to ctrl.
Figure 5 Cytokine and chemokine production by isolated LPL from colitic mice treated with CB.219. LPL prepared from colon tissue
of mice with established colitis and subsequent repeated treatment with CB.219 or with control IgG (ctrl) were cultured for 48 h
before concentrations of secreted factors were determined from the culture supernatants. Median and range of n = 7–10.
22 CB.219 therapy reduces humanized transfer colitisof colitis in Rag1-ko mice after transfer of CD4+CD45RBhi T
cells from huCD2tg mice was monitored every third day before
antibody treatment started on day 22 and continued up to day
59 (Fig. 4A). Establishment of colitis was confirmed by weight
loss and elevated stool scores as clinical signs (data not
shown). At day 21, mucosal and submucosal leukocyte
infiltration, hyperplastic crypts and occasional crypt abscesses
confirmed colitis histologically (Fig. 4B). While all
CB.219-treated mice survived throughout the experiment,
the severity of colitis in the control group reduced the
survival by about a third at the end of the study (Fig. 4C).
Upon CB.219 treatment, the stool score reverted to normal
levels within 10 days and worsened in the control group
until a plateau level was reached after 15 days (Fig. 4D).
Comparable to the preventive treatment, mice continu-
ously gained weight in the therapeutic approach with
CB.219 but lost it during treatment with the control
antibody (Fig. 4E). At the end of the experiment,
CB.219-treated mice presented with a significant weight
gain compared to the group of colitic mice treated with
control IgG (Fig. 4 F). Significantly diminished inflamma-
tion in colon and terminal ileum compared to the control
group after 37 days of repeated CB.219 treatment
underlined the therapeutic efficacy of CB.219 (Fig. 4G).
In surviving mice, therapeutic treatment with CB.219
exerted no influence on the spontaneous secretion of IFNγ in
ex vivo cultures of complete colon tissue but IL-2 and IL-10
tended to be tenfold lower while TGFβ was about 25fold
up-regulated in comparison to colon tissues of mice from the
control group (Table 2). In ex vivo cultures of complete
terminal ileum IFNγ and IL-10 was up-regulated like from
cultured colon tissues. Different from the colon in thera-
peutic treatment and also from the terminal ileum uponconcurrent antibody application (see Fig. 2C), TGFβ was
significantly down-regulated by CB.219 treatment compared
to the control (Table 2).
Focusing on the potential of the lymphocyte fraction,
isolated LPL from CB.219-treated mice produced significantly
less pro-inflammatory IFNγ, IL-2, IL-17A or TNFα and
significantly less pleiotropic IL-6 in comparison to the controls
(Fig. 5). As in the complete colon, anti-inflammatory IL-4 and
IL-10 tended to be reduced upon CB.219 treatment (Fig. 5).
Mainly attributing increased TGFβ production within the colon
tissue (see Table 2) to the non-lymphocyte fraction, LPL from
the colon of CB.219-treated mice produced TGFβ at the
same levels as those from control mice (Fig. 5). As for
chemotaxis-related factors, the CCL3 was significantly
down-regulated upon CB.219 treatment, while CCL2
and CXCL1 only showed a tendency in the same direction
(Fig. 5).
Proliferation of LPL prepared from CB.219-treated colitic
mice was significantly suppressed compared to that from
control animals (Fig. 6A). This also correlated to the in situ
finding of lower numbers of proliferating Ki67+ and apoptotic
CD95+ or cleaved caspase-3+ cells in colon sections of
CB.219-treated mice in comparison to controls (Fig. 6B). The
overall reduced potential for cytokine production was
reflected by a lower occurrence of F4/80+ macrophages and
CD3+ T cells in the colon of CB.219-treated mice compared to
that from control animals (Fig. 6C). Especially in line with
reduced colonic IL-2 production, numbers of Foxp3+ Treg were
low in the intestinal mucosa after therapeutic application of
CB.219 (Fig. 6D). The correlation between disease severity
and Treg numbers (Fig. 6E) highlighted the capacity of
targeting human CD2 applying CB.219 to revert clinical signs
of established T-cell-mediated colitis.
Figure 6 Immune cell infiltration of the colon tissue after therapeutic treatment with CB.219. (A) LPL isolated from CB.219 or
control IgG (ctrl) treated mice were directly subjected to a proliferation assay. Proliferation index was calculated from cultures with
and without stimulation via CD3/CD28. Median and range of n = 6–10. Thin sections of colon tissues were stained by
immunohistochemistry (B) for Ki67, CD95 or cleaved caspase-3, (C) for F4/80 or CD3 or (D) for Foxp3. Positive cells were counted
in 10 hpf. Median and range of n = 8–10. (E) Correlation between the histologic score and the occurrence of Foxp3+ Treg of colon
sections for individual mice that were treated with CB.219 (n = 10) or control IgG (ctrl) (n = 8). Coefficient of determination for the
correlation is given.
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Strategies targeting T-cell activity are still under investiga-
tion especially for treatment of auto-immune diseases or in
transplantation [35]. MEDI-507, a humanized anti-human
CD2 monoclonal antibody, is so far clinically approved to
induce donor-specific unresponsiveness in allogeneic stem
cell transplantation [24]. Activated T cells play a crucial role
in the vicious circle of the recurrent dysbalanced mucosal
immune system in IBD [36]. Therefore, intestinal inflamma-
tion in IBD remains a potential target for CD2-directed
treatment options. Our model where CD4+CD45RBhi T cells
from huCD2tg mice induced colitis in Rag1-ko mice focused
this study on human CD2 on T cells. The CD2 antibody clone
CB.219 had the potential not only to prevent development of
huCD2tg T-cell-mediated colitis but also to attenuate
established T-cell-mediated colitis. Here, repeated doses
of CB.219 also dampened the accompanying inflammation
within the liver (not shown) and in the terminal ileum.
What are the potential T-cell-related mechanisms? Deple-
tion of CD2+ cell is a potential mechanism for the efficacy of
CD2-specific antibodies [37]. The treatment with neither
antibody clone, 35.1, 8E5 or CB.219, depleted the transferred
huCD2tg T cells. Immunohistochemical analysis of colon
sections confirmed engraftment and proliferation of the
transferred huCD2tg T cells in case of 35.1- and 8E5-treatedanimals, while only CB.219 prevented further activation of
the initially engrafted T cells (not shown). In transfer colitis,
intestinal inflammation is induced by reconstitution of
immunodeficient mice with naïve T cells that do not contain
Treg [38]. The so-called induced Treg are converted from
Foxp3-CD4+ T cells by T-cell receptor-mediated antigen-specific
stimulation in the presence of IL-2 [39]. In vitro, the stimulation
of T cells via CD2 without T-cell receptor involvement can lead
to T-cell anergy alongwith Treg induction [40]. Rag1-komice do
not harbor Treg as characterized by the transcription factor
Foxp3 [41], and the transferred huCD2tg CD4+CD45RBhi T cells
were negative for Foxp3. The capacity to induce Treg was not
impaired in our model since Foxp3+ cells were detected within
the colon tissues of mice with transfer colitis. However, low
numbers of Foxp3+ cells within the groups of preventive or
therapeutic treatment with CB.219 correlating to weak
intestinal inflammation and high numbers of Foxp3+ cells within
the intestinal mucosa accompanying severe inflammation in the
presence of 8E5, 35.1 or control IgG excluded a central role of
Treg-mediated control of intestinal inflammation. These
findings are underlined by low production of the Treg marker
cytokines IL-10 and TGFβ as well as by low colonic IL-2 levels
upon CB.219 treatment of established transfer colitis. Treat-
ment with CB.219 specifically reduced alterations in the
intestinal epithelium in terms of negligible apoptosis and the
lack of hyperproliferation of epithelial cells.
24 CB.219 therapy reduces humanized transfer colitisAs for another variant, a bound anti-CD2 monoclonal
antibody inhibiting binding of human CD2 to its ligand
CD58 on antigen-presenting cells could impede the
formation of an immunological synapse and the subse-
quent co-stimulation-dependent T-cell activation [42,43].
Initially, a series of monoclonal antibodies defined the
three main functional epitopes T111-T113 on the extracel-
lular part of the CD2 molecule [44,45]. Although the
antibodies CB.219 and 8E5 bind to T111 comprising the
domain for CD58 binding [31,46], differences in the
outcome support the assumption of overlapping antibody
binding sites with variant functionalities [47,48]. The effect
of CB.219 in established T-cell-mediated colitis points to
similarities with MEDI-507 for which was earlier suggested
that its binding regions share attributes with the T112 or
T113 domains [47]. Binding of anti-CD2 monoclonal anti-
bodies to the extracellular domain of the CD2 molecule
could down-modulate surface CD2 and induce
hypo-responsiveness [48], a mechanisms that might have
contributed to the beneficial effect of CB.219 in the
T-cell-mediated colitis. In man, T-cell receptor-mediated
and CD3-dependent T-cell activation is predominantly
found within the periphery while in the gut LPL more
strongly respond to CD2-mediated triggers [15].5. Conclusions
The chronic phase of active intestinal inflammation in
human IBD depends on T cells while natural killer cells are
diminished within the gut tissues [49]. Therefore, our
findings that CB.219 targeting human CD2 especially on T
cells not only prevents onset of T-cell-mediated colitis, but
also abrogates established colitis revives the potential of
CD2 targeting to specifically address intestinal inflamma-
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